Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Vertex/GSK, Vertex/Janssen, Boehringer Ingelheim/Ensemble

Executive Summary

Disparate events including Hurricane Sandy, extended-release generics, drug compounding and biopharma deal-making each highlighted just how important a challenge quality has become in the industry.

You may also be interested in...



Pharma Responds To Sandy’s Wrath With Delays

As the East Coast braces for the impact of Hurricane Sandy, companies choose the safety of their employees over keeping financial releases on schedule.

FDA’s Compounding Oversight: What Price Safety?

As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.

FDA And Generic Drug Quality: Turning Point, Or Precipice?

OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel